Roche announced June 27 that the U.S. FDA has issued 510(k) clearance for the company's CSF Aβ42/total-tau assay to be used for the diagnosis of Alzheimer’s disease in people aged 55 and older. The ...

In a recent study published in JAMA Neurology, an international team of researchers evaluated whether plasma phosphorylated tau 217 (p-tau217) could classify amyloid β (Aβ) status in cognitively ...